A Randomized Controlled Trial of an Extended Reality-Based Occupational Therapy Intervention to Improve Leisure Participation in Inpatients With Persistent Mental Health Conditions

The goal of this clinical trial is to evaluate the effects of an extended reality (XR)-enhanced occupational therapy leisure intervention on motivation, emotional engagement, and therapeutic participation among inpatients with chronic psychiatric conditions. The main questions it aims to answer are:
Can the XR intervention improve leisure motivation, leisure-related attitudes, and emotional coping strategies in long-term hospitalized individuals with mental illness?
Does the XR intervention promote improvements in psychological health, volition, and occupational performance?
Researchers will compare an XR-based leisure therapy group to a usual care group engaged in standard hospital leisure activities such as art, music, or reading. Participants will take part in weekly 40-minute sessions for 6 weeks. The XR group will use a custom-designed mobile VR program featuring immersive 360° leisure scenarios aligned with participants' interests and functional goals. Data collection includes standardized assessments (e.g., Interest Checklist, Volitional Questionnaire, COPM, PANSS) and semi-structured interviews to explore changes in motivation, coping, and perceived benefits.

Start Date01 Jul 2025

Sponsor / Collaborator

Chung Shan Medical University

NCT07018102

/ Not yet recruitingNot ApplicableIIT

Nurse-Led Bedside Trunk Control Care Program for Patients With Stroke

This study aimed to apply care for stroke survivors by establishing trustable professional activities competency indicators and a trunk control care module for rehabilitation ward nurses during our second year.

Start Date01 Jun 2025

Sponsor / Collaborator

Chung Shan Medical University

NCT06956287

/ RecruitingNot ApplicableIIT

The Efficiency of a New Sperm-Wash Device for Intrauterine Insemination in Couples With Infertility

This study evaluates the effectiveness of a novel sperm-wash device designed to improve outcomes in intrauterine insemination (IUI) for couples with infertility. Traditional sperm preparation methods, such as density gradient centrifugation (DGC), are associated with elevated reactive oxygen species (ROS) levels and increased sperm DNA fragmentation, potentially compromising pregnancy rates. The new device aims to reduce these adverse effects by minimizing oxidative stress and preserving sperm DNA integrity.
In this prospective, randomized controlled trial, 120 couples will be allocated to either the intervention group using the new device or the control group using DGC. The primary outcome is the clinical pregnancy rate, while secondary outcomes include sperm DNA fragmentation. The study hypothesizes that the novel device will result in higher pregnancy rates and reduced DNA fragmentation compared to DGC. These findings may support its use as a more physiological approach to sperm preparation in fertility treatment.

Start Date24 Apr 2025

Sponsor / Collaborator

Chung Shan Medical University

100 Clinical Results associated with Chung Shan Medical University

0 Patents (Medical) associated with Chung Shan Medical University

9,501

Literatures (Medical) associated with Chung Shan Medical University

31 Dec 2025·Channels

Biophysical and structural mechanisms of epilepsy-associated mutations in the S4-S5 Linker of KCNQ2 channels

Article

Author: Wong, Swee-Hee ; Lee, Inn-Chi ; Yang, Yen-Yu ; Yang, Shi-Bing ; Chang, Hsueh-Kai

Mutations in KCNQ2 are linked to various neurological disorders, including neonatal-onset epilepsy. The severity of these conditions often correlates with the mutation's location and the biochemical properties of the altered amino acid side chains. Two mutations affecting aspartate at position 212 (D212) in the S4-S5 linker of KCNQ2 have been identified. Interestingly, while the charge-conserved D212E mutation leads to severe neonatal-onset developmental and epileptic encephalopathy (DEE), the more dramatic substitution to glycine (D212G) results in self-limited familial neonatal epilepsy (SLFNE), a much milder pathology. To elucidate the underlying mechanisms, we performed electrophysiological studies and in silico simulations to investigate these mutations' biophysical and structural effects. Our findings reveal that the D212E mutation stabilizes the channel in the voltage sensor down-state and destabilizes the up-state, leading to a rightward shift in the voltage-dependent activation curve, slower activation kinetics, and accelerated deactivation kinetics. This disruption in KCNQ2 voltage sensitivity persists even in the more physiologically relevant KCNQ2/3 heterotetrameric channels. In contrast, the D212G mutation primarily destabilizes the up-state, but its impact on voltage sensitivity is significantly reduced in KCNQ2/3 heterotetrameric channels. These findings provide key insights into the biophysical and structural basis of KCNQ2 D212 mutations and their contribution to epilepsy-related symptoms, offering a clearer understanding of how these mutations drive the varied clinical outcomes observed in patients.

31 Dec 2025·Emerging Microbes & Infections

Prevalence and treatment outcomes of latent tuberculosis infection among older patients with chronic obstructive pulmonary disease in an area with intermediate tuberculosis burden

Article

Author: Sheu, Chau-Chyun ; Lee, Meng-Rui ; Chien, Jung-Yien ; Cheng, Meng-Hsuan ; Huang, Hung-Ling ; Huang, Wei-Chang ; Wang, Jann-Yuan ; Chong, Inn-Wen ; Yang, Jinn-Moon ; Lu, Po-Liang

ABSTRACTChronic obstructive pulmonary disease (COPD) and aging both increase the risk of tuberculosis (TB), an important infectious disease in human. Exploring the burden and predictors of latent tuberculosis infection (LTBI) and treatment outcomes for older individuals with COPD is essential to guide LTBI intervention policy. We enrolled patients aged over 60 years with COPD between January 2021 and June 2023 for LTBI screening using interferon-gamma release assay (IGRA). LTBI treatment options included all World Health Organization (WHO)-recommended regimens. The final regimen was selected through shared decision-making between patients and their COPD physicians, leveraging the long-standing rapport being established. We investigated the prevalence of LTBI in this population, identified risk factors using logistic regression analysis, and evaluated treatment outcomes. A total of 810 COPD patients (mean: 72.8-years) underwent LTBI screening, with an IGRA-positive rate of 23.8%. IGRA positivity was correlated with smoking pack-years (adjusted odds ratio [aOR]: 1.02, p < 0.001), current smoking status (aOR 1.40, p = 0.030), COPD duration (aOR 1.10, p = 0.03), inhaled corticosteroid use (aOR 3.06, p < 0.001), and a cumulative equivalent dose of prednisolone exceeding 210 mg over 2 years (aOR 3.13, p < 0.001). Treatment was initiated in 150 patients (77.7%), predominantly with weekly rifapentine plus isoniazid (3HP) (60.7%). The overall completion rate was 82.0%, with adverse reactions being the primary reason for discontinuation. Our findings support that the LTBI intervention is recommended for older patients with COPD, especially those at higher risk, as nearly 25% of them have tuberculosis infection. The high treatment completion rate highlights the safety and feasibility of the WHO-recommended regimens.

31 Dec 2025·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Thermal ablation included in multimodality treatment predicts enhanced survival in advanced non-small cell lung cancer: a propensity score-matched outcome study

Article

Author: Ku, Yueh-Han ; Wu, Tzu-Chin ; Tsai, Stella Chin-Shaw ; Chen, Yi-Min ; Liao, Pin-Hsu ; Lin, Frank Cheau-Feng ; Hsu, Chia-Hsuan ; Hsiao, Tzu-Hsuan

BACKGROUND:

Advanced non-small cell lung cancer (NSCLC) presents significant treatment challenges, with limited effective therapies for late-stage patients. This study aimed to evaluate the impact of adding thermal ablation (TA) in treatment regimens for advanced NSCLC to improve survival outcomes.

METHODS:

A retrospective cohort study was conducted at a medical center in Taiwan, analyzing data from 1,083 patients diagnosed with stage IIIB or IV NSCLC between 2008 and 2020. Survival outcomes were compared between patients treated with TA and those who received conventional therapies. Statistical analyses, including propensity score matching and Cox regression models, were used to account for potential confounders.

RESULTS:

The TA group demonstrated a significantly longer median overall survival (OS) of 37 months compared to 15 months in the non-TA group (p < 0.001), with five-year OS rates of 32.4% and 9.8%, respectively. Median progression-free survival (PFS) was 36 months in the TA group versus 14 months in the non-TA group, with five-year PFS rates of 24.1% versus 6.3% (p < 0.001). Subgroup analyses showed enhanced survival in patients undergoing targeted therapy and chemotherapy when TA was included. Survival outcomes with TA were comparable to lobectomy, offering a less invasive option for selected patients.

CONCLUSIONS:

Thermal ablation is associated with significant improvements in OS and PFS in patients with advanced NSCLC, providing a viable treatment option for those not eligible for surgery. The results support the integration of TA into standard care protocols, with further prospective studies needed to confirm these findings and optimize treatment strategies.

News (Medical) associated with Chung Shan Medical University

15 Mar 2024

·www.healthcareitnews.com

Gleneagles Hospital zeroes in on radiology AI and more briefs

Gleneagles Hospital, part of the international private hospital group IHH Healthcare, has partnered with medical AI providers to bolster its diagnostics capability in Singapore and Hong Kong. On one hand, the radiology department at Gleneagles Hong Kong will be adopting Australian company Annalise.ai's AI solution for analysing chest X-rays and CT brain scans Gleneagles Singapore, on the other hand, will be integrating South Korean company Lunit's AI-powered mammography analysis solution, Lunit INSIGHT MMG, into its breast screening workflow. Taiwan looks to validate Lunit's AI for its national cancer screening Alongside the Gleneagles contract, Lunit will also be providing its chest X-ray software, Lunit INSIGHT CXR, to Chung Shan Medical University in Taiwan. The solution is intended to be validated for potential integration into Taiwan's national cancer screening program. Ex-Bitsmedia CEO joins Doctor Anywhere Doctor Anywhere, a telemedicine provider in Southeast Asia, has recently announced the appointment of Louis-Bernard Carcouet as its VP of Product. Carcouet was the former CEO of Bitsmedia, the company behind the Muslim lifestyle app, Muslim Pro. He was also previously with Asia-focused property portal, PropertyGuru, as product manager. Based on a press statement, Carcouet will lead DA's product strategy, focusing on improving user experience across platforms. "Louis’ long history of product innovation and leadership in the tech industry, coupled with his passion for improving healthcare, make him an invaluable addition to the DA team," DA founder and CEO Lim Wai Mun said about his appointment. "We’ve seen how technology has been a catalyst for healthcare, in enhancing patient experiences and driving positive outcomes. With a relentless focus on user-centric design and innovation, I’m excited to collaborate with our team to build products that truly make a difference in people’s lives," Carcouet also commented.

Executive Change

12 Mar 2024

·www.nsmedicaldevices.com

Lunit expands AI medical imaging solutions in Taiwan and Singapore

Lunit will provide its AI-powered INSIGHT CXR solution for the detection of chest abnormalities to the Chung Shan Medical University in Taiwan, and INSIGHT MMG solution for mammography analysis, to the Gleneagles Hospital in Singapore Lunit’s AI-powered chest X-ray analysis solution INSIGHT CXR. (Credit: PRNewswire/ Lunit) Medical AI company Lunit has teamed up with the Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore, expanding into the East and Southeast Asian regions. Under the partnership, Lunit will supply its INSIGHT CXR solution for the detection of chest abnormalities to Chung Shan Medical University in Taiwan. The medical device maker will also provide its INSIGHT MMG solution for mammography analysis, to the Gleneagles Hospital in Singapore. Lunit CEO Brandon Suh said: “As demand for cutting-edge medical services continues to rise across East and Southeast Asia, Lunit is proud to spearhead the advancement of AI-powered solutions for cancer diagnostics in the region. “Our strategic partnerships with Chung Shan Medical University and Gleneagles Hospital Singapore strengthen our presence and open new opportunities across the market. “We believe that these contracts will pave the way for innovative approaches to cancer detection, ultimately improving patient outcomes in areas where they are most crucial.” Through the partnership with Chung Shan Medical University (CSMU), Lunit will modernise Taiwan’s national lung cancer screening programme, which currently depends on low‐dose computed tomography (LDCT) in high-risk individuals. CSMU will validate Lunit’s INSIGHT CXR solution for potential integration into the national cancer screening programme. The university will evaluate its ability to detect individuals more accurately and effectively, expanding the screening to a wider group beyond high-risk individuals. Also, Lunit will deliver its AI-powered mammography analysis solution INSIGHT MMG to Gleneagles Hospital in Singapore, a private healthcare facility within the IHH group. By integrating Lunit’s advanced technology into its breast screening workflow, the hospital aims to enhance its screening accuracy and operational efficiency. Earlier this year, Lunit signed a three-year supply contract with Samsung Electronics (Samsung Healthcare), to integrate its AI technology into Samsung’s premium X-ray devices. Under the partnership, Lunit will provide Samsung Electronics with two of its AI-powered chest screening solutions, Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage.

11 Mar 2024

·www.prnewswire.com

Lunit Expands AI Medical Imaging Solutions in East & Southeast Asia: Partners with Chung Shan Medical University and Gleneagles Hospital Singapore

AI-powered Lunit INSIGHT CXR and Lunit INSIGHT MMG to enhance lung and breast cancer detection in Taiwan and Singapore SEOUL, South Korea, March 11, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced two supply contracts that mark its strategic expansion into the East and Southeast Asian region. Lunit will supply its Lunit INSIGHT CXR for chest abnormality detection and Lunit INSIGHT MMG for mammography analysis to the Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore, respectively. Chung Shan Medical University to Pioneer AI in Lung Cancer Detection Continue Reading (from left to right) Lunit's AI-powered chest X-ray analysis solution "Lunit INSIGHT CXR" and Lunit's AI solution for mammography analysis "Lunit INSIGHT MMG" Under the newly inked supply contract, Lunit will collaborate with the prestigious Chung Shan Medical University (CSMU), Taiwan's leading medical university. This collaboration holds the potential to revolutionize Taiwan's national lung cancer screening program. Compared to Taiwan's current screening program, which relies on low‐dose computed tomography (LDCT) for screening high-risk individuals such as smokers or those with a family history of lung cancer, CSMU aims to validate Lunit INSIGHT CXR for potential integration into the national cancer screening program. The goal is to assess its ability to detect individuals more accurately and efficiently, potentially expanding the screening to a broader group beyond high-risk individuals. This approach could significantly advance Taiwan's efforts to enhance early detection and improve outcomes in lung cancer screening. Gleneagles Hospital Singapore Chooses Lunit for Enhanced Breast Cancer Screening In a parallel move, Lunit is set to deliver its AI-powered mammography analysis solution, Lunit INSIGHT MMG, to Gleneagles Hospital in Singapore, a prominent private healthcare facility within the IHH group. Gleneagles plans to enhance screening accuracy and operational efficiency by seamlessly integrating Lunit's cutting-edge technology into its breast screening workflow. Gleneagles Hospital, part of Southeast Asia's largest medical group, IHH, is a leading private healthcare provider in the region. Recognized with the Singapore Quality Class certification, the hospital offers extensive clinical facilities with 221 beds, emphasizing its commitment to exceptional standards in healthcare. "As demand for cutting-edge medical services continues to rise across East and Southeast Asia, Lunit is proud to spearhead the advancement of AI-powered solutions for cancer diagnostics in the region," said Brandon Suh, CEO of Lunit. "Our strategic partnerships with Chung Shan Medical University and Gleneagles Hospital Singapore strengthen our presence and open new opportunities across the market. We believe that these contracts will pave the way for innovative approaches to cancer detection, ultimately improving patient outcomes in areas where they are most crucial." About Lunit Founded in 2013, Lunit is a deep learning-based medical AI company on a mission to conquer cancer. We are committed to harnessing AI to ensure accurate diagnosis and optimal treatment for each cancer patient using AI-powered medical image analytics and AI biomarkers. As a medical AI company grounded on clinical evidence, our findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and the Lancet Digital Health, and global conferences, including ASCO and RSNA. After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 3,000+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io. SOURCE Lunit

100 Deals associated with Chung Shan Medical University

100 Translational Medicine associated with Chung Shan Medical University

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 28 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Isoquercetin	Lung Injury More	Preclinical
Jing Ceih Shern Yuan Extract Pill	Osteoarthritis More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis